Top

Published in:

01-10-2011 | Original Article

The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer

Authors: Kenji Shibuta, Hiroaki Ueo, Hidemi Furusawa, Kansei Komaki, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihiko Kamada, Nobumitsu Tamaki

Published in: Breast Cancer | Issue 4/2011

Abstract

Background

Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported.

Methods

Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively.

Results

The following subtype distribution was observed: luminal A type (ER+ and/or PgR+, HER2−), 3,046 cases (71%); luminal B type (ER+ and/or PgR+, HER2+), 321 cases (8%); HER2 type (ER−, PgR−, HER2+), 398 cases (9%); and triple negative (TN) type (ER−, PgR−, HER2−), 501 cases (12%). The HER2+ subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes.

Conclusion

Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments.

Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 15th ed. Tokyo: Kanehara-Shuppan Co.; 2004; p. 31–68.

National Registration Survey of Breast Cancer Patients (2005 annual cases). Japanese Breast Cancer Society Registration Committee. 2005;36:1–20 (in Japanese).

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRef

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–8.PubMedCrossRef

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jefferey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.PubMedCrossRef

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA.. 2003;100:8418–23.PubMedCrossRef

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–502.PubMedCrossRef

Nakajima H, Fujiwara I, Mizuta N, Sakaguchi K, Hachimine Y, Nakatsukasa K, et al. Investigation of the prognosis of breast cancer from the view point of presentation of estrogen receptor and HER2 in immunohistochemical staining. Jpn Clin Surg. 2007;68:2171–77 (in Japanese with English abstract).

10.

Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15:303–8.PubMedCrossRef

11.

Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007;16:s72–7.PubMedCrossRef

12.

Kurebayashi J. Characteristics of breast cancers in Japanese patients according to the gene expression profiles. Clin Surg. 2008;63:1055–9 (in Japanese).

13.

Ishihara A, Tsuda H, Kitagawa K, Yoneda M, Shiraishi T. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features. Breast Cancer. 2009;16:179–85.PubMedCrossRef

14.

Okumura Y, Nishimura R, Osako T. Is chemotherapy necessary for young women with breast cancer? Jpn J Breast Cancer. 2009;24:23–9 (in Japanese with English abstract).

15.

Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E ^high/p27 ^low/p53⁺/glomeruloid-microvascular-proliferation⁺) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830–5.PubMedCrossRef

16.

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.PubMedCrossRef

17.

Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–81.PubMedCrossRef

18.

Piccart GMJ, Procter M, Leyland JB, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRef

19.

Romond EH, Perez EA, Bryant JB, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef

Title: The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer
Authors: Kenji Shibuta
Hiroaki Ueo
Hidemi Furusawa
Kansei Komaki
Yoshiaki Rai
Yoshiatsu Sagara
Yoshihiko Kamada
Nobumitsu Tamaki
Publication date: 01-10-2011
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-010-0209-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2011

Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-term outcome of 36 malignant phyllodes tumors

Synchronous benign-appearing calcifications in patients with ductal carcinoma in situ may not be benign

A case of a fibroadenoma coexisting with an invasive lobular carcinoma in the breast

Radiotherapy strategies for recurrent and metastatic breast cancer

Management of locoregional recurrence of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer